- Immunovant (IMVT) appoints new CEO and CFO in alignment with Roivant's strategic realignment.
- Expansion of IMVT-1402 to include new indications: Sjögren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE).
- Current cash reserves expected to support operations through 2027.
Immunovant, Inc. (IMVT), a clinical-stage immunology company focused on autoimmune diseases, has announced pivotal changes in its leadership alongside an expansion of its IMVT-1402 development program. Eric Venker, M.D., previously President and COO of Roivant, has assumed the role of CEO at Immunovant, succeeding Pete Salzmann who has retired. Tiago Girao has been appointed as CFO, replacing Renee Barnett.
The company has unveiled two new indications for IMVT-1402: Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE). An Investigational New Drug (IND) application has been cleared for a potentially registrational program targeting SjD, with studies anticipated to commence by summer 2025. Meanwhile, a proof-of-concept study has been initiated for CLE, marking IMVT-1402's sixth indication.
Immunovant confirmed that its current cash balance is adequate to sustain operations through the anticipated data readout for Graves’ Disease in 2027. These developments occur within a broader strategic shift involving increased operational participation and strategic oversight by Roivant.
Further to these changes, Roivant will manage all investor relations activities for Immunovant, and a live conference call is scheduled for 8:00 a.m. EDT on Monday, April 21, 2025, to elaborate on these updates.
